Top Fully Remote Pharmaceutical Companies (6)
Maisha Meds has created the first and largest network of private pharmacies and clinics in East Africa through a mobile app that delivers subsidized care. Not only does the app now help over 3,500 businesses operate by making sales, managing inventory, and tracking patients; it also reimburses them for providing affordable care to patients for malaria, birth control, and HIV prevention. By harnessing the power of a vast but fragmented private sector, our program improves access for patients, supports pharmacies that often serve as a first point of contact, and generates vital research and data on global health and market trends.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and their patients.
Third Harmonic Bio is a clinical-stage biopharmaceutical company developing a highly selective, oral KIT inhibitor for treatment of dermal, respiratory and gastrointestinal inflammatory diseases. KIT is a cell surface receptor that acts as the master survival and functional regulator of mast cells, which are immune cells concentrated at the body’s interfaces with the external environment and that act as the key mediator of the inflammation associated with mast-cell mediated inflammatory diseases. By inhibiting KIT, we believe we can provide broad symptomatic relief to patients with a range of disorders, including chronic spontaneous urticaria and severe asthma
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of transformational therapies for autoimmune diseases. We are leveraging the extensive drug development expertise of our team to acquire best-in-class assets against compelling targets, and applying them to disease areas with significant unmet need. Timberlyne’s lead program, CM313, is an IgG1 monoclonal antibody with enhanced complement-dependent cytotoxicity that targets CD38. By targeting CD38, highly expressed on plasma cells, NK cells, and other immune cells, CM313 can modulate multiple arms of the immune system leading to both rapid and durable responses across a range of autoimmune diseases. CM313 has been tested in numerous disease states including Immune Thrombocytopenia, Systemic Lupus Erythematosus, and relapsed/refractory Multiple Myeloma. Timberlyne plans to develop CM313 across a broad range of autoimmune indications. Launched in 2024, Timberlyne has raised $180 million from leading life sciences investors.
Motitus is a consulting firm specializing in biotechnology, pharmaceuticals, healthcare, life sciences, and health tech, working with ambitious leaders. We bridge the gap between thinking and implementation with extraordinary impact. We deliver mission projects that transform your business into state-of-the-art for the industry. The word Motitus carries a compelling narrative that resonates deeply within the realms of healthcare and innovation. The name itself, derived from the Latin word for "movement," encapsulates the essence of progress, dynamism, and transformation—qualities that are vital in the fast-evolving landscape of health and medicine. From its inception, Motitus aimed to be more than just a consultancy; it sought to be a catalyst for change. The brand's identity is built around the concept of movement, representing the fluidity and adaptability required in modern healthcare. Whether it’s helping a pharmaceutical company navigate regulatory hurdles or assisting a biotech startup in bringing its product to market, Motitus embodies the spirit of progress and agility.
ArriVent is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep and global network, ArriVent seeks to access unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs. Through strategic collaborations with innovative biopharma companies, ArriVent aims to globalize medicines for patients with unmet medical need in a broad range of diseases, with an initial focus in oncology.
Work Your Passion. Live Your Purpose.
